RT Journal Article
T1 Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
A1 Moreno-Arribas, José
A1 Bertomeu-González, Vicente
A1 Anguita-Sanchez, Manuel
A1 Cequier, Ángel
A1 Muñiz, Javier
A1 Castillo, Jesús
A1 Sanchis, Juan
A1 Roldán, Inmaculada
A1 Marín, Francisco
A1 Bertomeu-Martínez, Vicente
A1 investigators of the FANTASIIA study, 
K1 anticoagulant treatment
K1 atrial fibrillation
K1 nonvitamin K antagonist oral anticoagulants
K1 vitamin K antagonists
AB Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Mean age was 73.8 ± 9.4 years, and 42.5% of the patients were women. The CHA2DS2-VASc score was 0 in 4.9% of the population, 1 in 24.1%, and ≥2 in 71% (median = 4, interquartile range = 2). Variables associated with NOAC treatment were major bleeding (odds ratio [OR] = 3.36; confidence interval [CI] 95%: 1.73-6.51; P  Medical and social variables were associated with prescription of NOAC. Major bleeding, hemorrhagic stroke, university education, and higher glomerular filtration rate were more frequent among patients under NOAC. On the contrary, patients with history of cancer or bradyarrhythmias more frequently received VKA.
YR 2015
FD 2015-07-30
LK http://hdl.handle.net/10668/10027
UL http://hdl.handle.net/10668/10027
LA en
DS RISalud
RD Apr 19, 2025